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EDITORIAL
IgA nephropathy: A stem cell disease?
Despite intensive investigation by several groups, a abnormality have suggested that abnormal T-lympho-
cyte function drives the increased IgA production by Bwidely accepted hypothesis for the pathogenesis of immu-
noglobulin A (IgA) nephropathy has not yet emerged. cells. Specifically, the number of T helper (Ta4) lympho-
cytes, which are endowed with the capacity to switch BMost data available so far are consistent with the possi-
bility that immunological dysfunction plays an important cells from IgM to IgA synthesis, is increased in patients
with IgA nephropathy. In further support of a role forrole [1]. Thirty-five to 50% of patients with IgA nephrop-
athy have elevated serum IgA levels, especially of the Ta4 cells, increased frequency of the Sa1 allele, the por-
tion of the gene that mediates the switch from IgM toIgA1 subclass derived from bone marrow. This circulat-
ing IgA is partly macromolecular, and the deposited IgA IgA, has been shown in patients with IgA nephropathy
[2]. Investigation into the pathogenesis of IgA nephropa-in the mesangium can be eluted from the glomeruli as
polymeric IgA1. Whether in IgA nephropathy the circu- thy has been flawed by the difficulty in developing a
suitable animal model. The study presented in this issuelating IgA1 is bound to antigens in the form of immune
complexes is still a controversial issue. No single major of Kidney International by Imasawa and co-workers [4]
is based on the experimental model of high IgA producerinfectious pathogen has been identified as a potential
source of antigen, in spite of the well-known recurrence (HIGA) ddY mice, which spontaneously develop mesan-
gial IgA deposition by approximately 25 weeks of age.of acute disease after infectious episodes at the mucosal
level. The failure to identify specific antigens has led While not too much emphasis may be given to the HIGA
mice as a model of human IgA nephropathy, in that noincreasingly to the view that polymeric IgA may be anti-
gen-independent, and that the circulating polymeric chronic renal impairment is demonstrated, this murine
model provides a useful tool to examine mechanisms ofIgAs are low-affinity, “natural” antibodies, generated by
polyclonal B-cell activation. Actually, peripheral blood the formation and possible significance of IgA deposits.
The authors hypothesized that the pathogenic agent ofB-cells from patients with IgA nephropathy have exhib-
ited abnormally high rates of IgA secretion either in the IgA nephropathy lies in bone marrow cells, based on
absence of stimuli or, more consistently, upon mitogen two earlier observations: 1) bone marrow cells (BMCs)
stimulation [2]. Several studies have also reported in- from IgA nephropathy-prone ddY mice transplanted
creased fractions of peripheral blood B-cells expressing into normal B6 mice increased the deposition of serum
surface IgA. However, it is unlikely that the excess macromolecular IgA and glomerular IgA in the recipi-
amount of circulating IgA is the sole cause of IgA renal ents [5]; 2) in a patient with IgA nephropathy and chronic
deposition, as indicated by the rare occurrence of IgA- myeloblastic leukemia, allogeneic bone marrow trans-
associated glomerular damage in acquired immune defi- plantation (BMT) not only cured the leukemia but also
ciency syndrome patients, despite very high levels of eliminated the mesangial IgA deposits. In the present
circulating IgA. The recent observation that circulating study, the authors document that HIGA mice trans-
IgA from patients with IgA nephropathy exhibits abnor- planted at around 25 weeks of age with allogeneic BMCs
mal glycosylation (a reduced galactosylation of O-linked from normal B6 mice develop less mesangial IgA and
glycans) suggests that mesangial deposition of IgA in complement C3 deposition and less severe glomerulo-
this disease might rather be due to intrinsic alterations sclerosis and mesangial matrix expansion compared to
of IgA1 [3]. their counterparts given HIGA BMCs.
Indeed, reduced galactosylation modifies the confor- These B6→HIGA mice also excreted less urinary al-
mational stability of the IgA1 molecule and consequently bumin than the HIGA→HIGA mice. Serum IgA levels,
the interaction of the IgA1 molecule with receptors and particularly macromolecular IgA, were lower than in
tissue proteins that may favor a reduced clearance and HIGA→HIGA mice. These data suggest the exciting
increased deposition in the mesangium. and provocative hypothesis that allogeneic BMT might
Investigators searching for an upstream immunologic be a tool for treating IgA nephropathy. However, major
issues remain to be addressed. For example, which types
of cells and what factors are defective at the stem cellKey words: galactosylation, HIGA mice, bone marrow transplantation,
T helper cells, bone marrow cells. level and play an important role in increasing serum
level of macromolecular IgA? 1999 by the International Society of Nephrology
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Since BMCs transplanted into both B6→HIGA and response against cellular antigen, are called for to clarify
the issue. In any case, the therapeutic efficacy of mixedHIGA→HIGA mice were equally exposed to the same
allogeneic-syngeneic BMTs on IgA production and IgA-environmental factors, the authors hypothesize that im-
mediated damage in HIGA mice is worth evaluating.munological differences in the two groups must lie in
What are the future therapeutic implications of thesethe BMCs. Although they do not deny a role for antigens
findings for human autoimmune disease? Patients with ain the pathogenesis of IgA nephropathy, they consider
hematological condition such as leukemia and/or aplasticthe antigen only as a stimulus to activate an abnormal
anemia and a concomitant autoimmune disease (mostlyresponse in dysfunctional BMCs. An alternative expla-
rheumatoid arthritis) have been reported to be curednation could be that in IgA nephropathy-prone mice
following allogeneic BMTs [9]. There are also a fewabnormal self antigens are inefficiently presented within
patients who have been treated in this way for theirthe thymus in such a way that autoreactive T helper
autoimmune disease alone.clones are generated and stimulate abnormal IgA pro-
However, the use of allogeneic BMT in non-malignantduction by B cells in the periphery. Experiments re-
disorders must be very carefully considered, in view ofported in the last few years [6], designed to investigate
toxicity and potential morbidity associated with it. Newthe mechanism that maintains tolerance to grafts in
non-myeloablative conditioning regimens, designed tomixed mouse allogeneic chimeras, have provided sub-
allow the donor’s immune system to take over, are al-stantial arguments linking BMT-induced donor-specific
ready utilized for malignant and non-malignant hemato-tolerance and thymic presentation of donor antigens to
logic diseases, and may become an attractive option foralloreactive T cells. In these mixed allogeneic chimeras,
severe, refractory autoimmune disease. As for the appli-induction of tolerance was associated with donor anti-
cability of BMT to treatment of human IgA nephropa-gen-presenting cells in the thymus, and the maintenance
thy, that cannot be foreseen at this time. Certainly, accu-of the tolerance state depended on the persistence of
rate comparisons with already existing protocols (withdonor antigens in the thymus. It is possible to infer that
angiotensin-converting enzyme inhibitors or steroids andthe mechanism(s) responsible for IgA correction by allo-
other immunosuppressive agents) currently used for ther-geneic BMTs in HIGA mice recognize a similar pattern
apeutic management of the disease [10] are mandatory.and that the allogeneic BMT provides antigens in the
thymus that effectively prevent generation of aberrant
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NOTE ADDED IN PROOFprimary humoral immune response and have a deficient
In a recent study (Nat Med 5:1018–1025, 1999) Zhengcellular immune response to certain intracellular patho-
et al documented that knockout mice manifesting defi-gens [8]. On the other hand, transplanting mixed bone
ciency of an anti-inflammatory protein uteroglobin (UG)marrow from both allogeneic autoimmune-resistant mice
develop almost all of the pathologic features of humanand syngeneic autoimmune-prone mice into lethally irra-
IgA. UG administration prevented glomerular accumu-diated recipients corrects the autoimmune disease in the
lation of exogenous IgA in UG-KO mice. These resultslupus-prone strain of mice and also avoids the annoying
provide a role for UG in preventing IgA nephropathy.immunodeficiencies produced by allogeneic BMTs [8].
Imasawa and co-workers [4] exclude immunodeficency
in their B6→HIGA allogeneic chimeras, based on data
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